DiscoveryProbe™ FDA-approved Drug Library: A Benchmark for High-Throughput Drug Screening

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) comprises 2,320 bioactive compounds with established clinical safety and efficacy profiles, each approved by at least one major regulatory agency (FDA, EMA, HMA, CFDA, or PMDA) (ApexBio). These compounds span diverse mechanisms, including receptor modulation, enzyme inhibition, and ion channel regulation, facilitating robust high-throughput and high-content screening (HTS/HCS) (Zhou et al., 2022). The pre-dissolved 10 mM DMSO format ensures reproducibility and stability for up to 24 months at -80°C. Rigorous benchmarking demonstrates successful discovery of small-molecule inhibitors for previously untargeted enzymes, such as the identification of Tideglusib as a Pif1 helicase inhibitor. The library robustly supports drug repositioning, pharmacological target identification, and mechanistic studies across oncology, neurodegenerative, and rare disease models.

Biological Rationale

The translation of clinically approved compounds into research screening offers a unique advantage. All 2,320 drugs in the DiscoveryProbe™ FDA-approved Drug Library have undergone comprehensive toxicology, pharmacokinetic, and efficacy evaluations in humans or advanced animal models (ApexBio). Their mechanisms of action encompass receptor agonism/antagonism (e.g., metformin for AMPK activation), enzyme inhibition (e.g., doxorubicin as a topoisomerase II inhibitor), ion channel modulation, and signal pathway regulation. This diversity enables systematic interrogation of cellular pathways relevant to oncology, neurodegeneration, metabolic, and rare disorders (Bridgene 2023). High-throughput screening (HTS) using such libraries can rapidly identify bioactive hits with established ADME/Tox profiles, reducing downstream attrition rates in drug development.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

Each compound within the DiscoveryProbe™ FDA-approved Drug Library is annotated with its primary and secondary mechanisms, as established in regulatory filings and peer-reviewed literature. For example, compounds include:

• Doxorubicin: DNA intercalation and topoisomerase II inhibition (used in multiple cancers).
• Metformin: AMPK agonism and mitochondrial complex I inhibition (antidiabetic and oncology research).
• Atorvastatin: HMG-CoA reductase inhibition (lipid-lowering agent, with emerging repositioning in neuroprotection studies).
• Tideglusib: Irreversible inhibition of Pif1 helicase and GSK-3β (recently validated in bacterial and human systems; see Zhou et al., 2022).

This mechanistic diversity ensures that HTS and HCS campaigns can interrogate a broad landscape of disease-relevant targets. Compounds are provided as 10 mM solutions in DMSO, compatible with robotic liquid handling and standardized screening workflows. Stability claims (12 months at -20°C and up to 24 months at -80°C) are validated by batch testing and solvent compatibility studies (ApexBio).

Evidence & Benchmarks

• Using a fluorescence polarization-based HTS of 1,917 FDA-approved compounds (including those in DiscoveryProbe™), Tideglusib was identified as the first small-molecule inhibitor of bacterial and human Pif1 helicase (IC₅₀ = 2–6.2 μM, 25°C, in Tris-HCl buffer, pH 7.5) (Zhou et al., 2022).
• DiscoveryProbe™-class libraries enable identification of both enzyme inhibitors and pathway modulators in complex cellular models suitable for oncology and neurodegenerative disease screens (GSKChem 2023).
• Drug repositioning efforts using FDA-approved compound libraries have led to repurposing clinical agents for rare diseases and novel mechanistic targets, reducing time-to-clinic (GSK3b 2023).
• All compounds are provided in DMSO at 10 mM, facilitating immediate use in HTS and minimizing compound degradation (ApexBio).
• Library stability and format flexibility (96-well, deep-well, 2D barcoded tubes) have been validated in independent screening centers (PrecisionFDA 2024).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is optimized for translational research, target identification, and drug repositioning. Its applications include:

• High-throughput screening for novel inhibitors or activators of disease-relevant enzymes and receptors.
• Mechanistic studies in oncology, neurodegenerative disease, metabolic disorders, and rare genetic conditions.
• Evaluation of drug–drug interactions using clinically relevant compounds.
• Rapid drug repositioning leveraging known pharmacokinetics and toxicology (SB-334867 2024).

Common Pitfalls or Misconceptions

• Not all compounds are approved for every indication in all countries: Regulatory status may vary (e.g., FDA vs. EMA); always confirm regional approvals.
• The library does not include investigational or preclinical molecules: Only compounds with clinical approval or pharmacopoeia listing are present.
• High-content screening requires appropriate controls: Phenotypic effects may reflect off-target actions; secondary validation is essential.
• Compound stability is guaranteed only under specified storage conditions: Deviations may compromise integrity.
• Library does not replace target validation steps: Hits require orthogonal confirmation and mechanistic follow-up.

This article extends the mechanistic and workflow details beyond the applications focus of DiscoveryProbe FDA-approved Drug Library: Transforming HTS, clarifying format, stability, and benchmarking practices. It also provides more recent data and mechanistic depth than Pioneering Functional Screening, particularly referencing the identification of Tideglusib as a Pif1 helicase inhibitor.

Workflow Integration & Parameters

• Formats: 96-well microplates, deep-well plates, and 2D barcoded screw-top tubes, all pre-dissolved at 10 mM in DMSO (ApexBio).
• Storage & Stability: Stable for 12 months at -20°C and up to 24 months at -80°C; QC testing confirms integrity and identity.
• Shipping: Evaluation samples shipped on blue ice; bulk shipments at room temperature or blue ice upon request.
• Compatibility: Solutions are directly compatible with robotic liquid handlers, standard HTS/HCS platforms, and biochemical/cell-based assays.
• Annotation: Each compound is supplied with CAS number, regulatory status, primary/secondary mechanism(s), and recommended assay conditions.
• Recommended Use: Thaw at room temperature, aliquot as required, avoid repeated freeze–thaw cycles.

For optimized integration, see also the workflow and strategic guidance in Translational Horizons, which offers a roadmap for mechanistic discovery and strategic screening using regulatory-vetted drug libraries.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a validated, versatile resource for high-throughput and high-content drug screening. Its comprehensively annotated, clinically approved compounds support mechanistic exploration, target identification, and drug repositioning across multiple therapeutic domains. Recent evidence, such as the discovery of Tideglusib as the first small-molecule Pif1 helicase inhibitor, underscores the library's impact in uncovering new pharmacological space (Zhou et al., 2022). By integrating this library into translational workflows, researchers can accelerate hit-to-lead campaigns, minimize risk, and maximize clinical relevance. Find further details, technical specifications, and purchasing options on the DiscoveryProbe™ FDA-approved Drug Library product page.